A recent study indicates that people who stop using new slimming jabs like Mounjaro or Wegovy may regain reduced body mass at a significantly accelerated pace than those who end traditional diet and exercise regimens.
Published data in a prominent health publication demonstrates that while overweight people often shed substantial amounts of their total mass while using the jabs, the mass returns at an average rate of 0.8 kg per month after stopping.
"Individuals using these treatments need to be informed of the risk of rapid rebound weight gain when the therapy concludes," cautioned lead investigator Dr. Susan Jebb.
Such speed of recovery implies a reversion to pre-treatment mass in about a year and a half.
Comparing Approaches
The study, which looked at dozens of studies involving over 9,000 of participants, compared the effects of GLP-1 agonists with older methods.
The team note that individuals who shed pounds through lifestyle changes alone usually have a slower creep back—approximately 0.1 kg a month—once they finish.
Understanding the Fast Regain
Doctors suggest the way of the jabs accounts for the heightened rebound.
These medications imitate a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Long-term administration of the hormone levels far above than the body's typical production may cause the body to generate a reduced amount of its own natural hormone, and could lessen sensitivity to its actions," said Dr. Adam Collins, a nutrition expert.
"Discontinuation of this hormone supplement results in appetite is unsuppressed, making excessive eating a significant risk."
A Lifelong Disease?
Medical guidelines recommend the injections for individuals with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications.
Many experts say that, given the high risk of weight regain, the therapy is often life-long.
This perspective is supported by pharmaceutical companies, who state that the findings "underscore the long-term character of obesity," akin to managing conditions like hypertension.
User Testimonies
Users who have come off the jabs report a powerful return of cravings.
"I experienced a trigger flipping and you become extremely hungry," described an individual.
This challenge is worsened if individuals have not established permanent dietary or behavioural modifications during therapy.
Growing Adoption
Survey data indicate that millions of adults in the UK have tried these injections in the past year, with desire remaining high.
- Use is more common among women than males.
- The middle-aged age group shows the highest level of interest.
- A large proportion obtain the medications through private prescriptions rather than the NHS.
Ultimately, researchers emphasize that while GLP-1 drugs are powerful agents for weight loss, they are not a permanent solution and lasting health benefits hinges on combined behavioural support.
